Brought to you by 
Merck KGAA signs agreement with Human Genome and SmithKline
02 Aug 2001
Executive Summary
Merck KGAA agreed to collaborate for five years with Human Genome Sciences and SmithKline Beecham on the development of pharmaceuticals from the database of gene fragments developed by HGS and SB in a deal worth $50mm to HGS.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Concluded
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck KGAA signs agreement with Human Genome and SmithKline
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice